Tags

Type your tag names separated by a space and hit enter

Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet.
Nutrition. 2013 Mar; 29(3):562-7.N

Abstract

OBJECTIVE

The scientific community is on the look-out for safe biomolecules useful in the prevention of obesity and related aberrations such as fatty liver. This study analyzed the influence of resveratrol on hepatic triacylglycerol metabolism.

METHODS

Male Sprague-Dawley rats were divided into control and resveratrol-treated groups (30 mg/kg of body weight per day) and fed a commercial obesogenic diet for 6 wk. Liver triacylglycerol content and the activity of carnitine palmitoyl transferase-Ia (CPT-Ia), acyl-coenzyme A oxydase (ACO), fatty acid synthase (FAS), glucose-6-phosphate dehydrogenase (G6PDH), malic enzyme (ME), acetyl-coenzyme A carboxylase (ACC), adenosine monophosphate-activated protein kinase (AMPK), and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) activation were measured. Mitochondrial protein cytochrome C oxidase subunit 2 (COXII), mitochondrial transcription factor A (TFAM), sterol regulatory element-binding protein-1c (SREBP-1c), peroxisome proliferator-activated receptor-α (PPAR-α), sirtuin-1 (SIRT1), hepatocyte nuclear factor receptor-4α (HNF-4α), and PGC-1α mRNA levels were also analyzed. Serum insulin was quantified.

RESULTS

Resveratrol decreased liver fat accumulation, increased CPT-Ia and ACO, and decreased ACC activities. Other lipogenic enzymes, FAS, ME, and G6PDH were not modified. The polyphenol activated AMPK and PGC-1α. The expression of SRBP-1c, PPAR-α, SIRT1, PGC-1α, HNF-4α, TFAM, and COXII was not modified. No changes in serum insulin levels were observed.

CONCLUSION

Resveratrol partly prevents the increase in liver fat accumulation induced by high-fat high-sucrose feeding by increasing fatty acid oxidation and decreasing lipogenesis. These effects are mediated by the activation of the AMPK/SIRT1 axis.

Authors+Show Affiliations

Nutrition and Obesity Group, Department of Nutrition and Food Science, Faculty of Pharmacy, University of the Basque Country-UPV/EHU, Vitoria, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23274094

Citation

Alberdi, Goiuri, et al. "Hepatic Lipid Metabolic Pathways Modified By Resveratrol in Rats Fed an Obesogenic Diet." Nutrition (Burbank, Los Angeles County, Calif.), vol. 29, no. 3, 2013, pp. 562-7.
Alberdi G, Rodríguez VM, Macarulla MT, et al. Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition. 2013;29(3):562-7.
Alberdi, G., Rodríguez, V. M., Macarulla, M. T., Miranda, J., Churruca, I., & Portillo, M. P. (2013). Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition (Burbank, Los Angeles County, Calif.), 29(3), 562-7. https://doi.org/10.1016/j.nut.2012.09.011
Alberdi G, et al. Hepatic Lipid Metabolic Pathways Modified By Resveratrol in Rats Fed an Obesogenic Diet. Nutrition. 2013;29(3):562-7. PubMed PMID: 23274094.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. AU - Alberdi,Goiuri, AU - Rodríguez,Víctor M, AU - Macarulla,M Teresa, AU - Miranda,Jonatan, AU - Churruca,Itziar, AU - Portillo,María P, Y1 - 2012/12/28/ PY - 2012/05/09/received PY - 2012/09/07/revised PY - 2012/09/10/accepted PY - 2013/1/1/entrez PY - 2013/1/1/pubmed PY - 2013/7/31/medline SP - 562 EP - 7 JF - Nutrition (Burbank, Los Angeles County, Calif.) JO - Nutrition VL - 29 IS - 3 N2 - OBJECTIVE: The scientific community is on the look-out for safe biomolecules useful in the prevention of obesity and related aberrations such as fatty liver. This study analyzed the influence of resveratrol on hepatic triacylglycerol metabolism. METHODS: Male Sprague-Dawley rats were divided into control and resveratrol-treated groups (30 mg/kg of body weight per day) and fed a commercial obesogenic diet for 6 wk. Liver triacylglycerol content and the activity of carnitine palmitoyl transferase-Ia (CPT-Ia), acyl-coenzyme A oxydase (ACO), fatty acid synthase (FAS), glucose-6-phosphate dehydrogenase (G6PDH), malic enzyme (ME), acetyl-coenzyme A carboxylase (ACC), adenosine monophosphate-activated protein kinase (AMPK), and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) activation were measured. Mitochondrial protein cytochrome C oxidase subunit 2 (COXII), mitochondrial transcription factor A (TFAM), sterol regulatory element-binding protein-1c (SREBP-1c), peroxisome proliferator-activated receptor-α (PPAR-α), sirtuin-1 (SIRT1), hepatocyte nuclear factor receptor-4α (HNF-4α), and PGC-1α mRNA levels were also analyzed. Serum insulin was quantified. RESULTS: Resveratrol decreased liver fat accumulation, increased CPT-Ia and ACO, and decreased ACC activities. Other lipogenic enzymes, FAS, ME, and G6PDH were not modified. The polyphenol activated AMPK and PGC-1α. The expression of SRBP-1c, PPAR-α, SIRT1, PGC-1α, HNF-4α, TFAM, and COXII was not modified. No changes in serum insulin levels were observed. CONCLUSION: Resveratrol partly prevents the increase in liver fat accumulation induced by high-fat high-sucrose feeding by increasing fatty acid oxidation and decreasing lipogenesis. These effects are mediated by the activation of the AMPK/SIRT1 axis. SN - 1873-1244 UR - https://www.unboundmedicine.com/medline/citation/23274094/Hepatic_lipid_metabolic_pathways_modified_by_resveratrol_in_rats_fed_an_obesogenic_diet_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0899-9007(12)00367-X DB - PRIME DP - Unbound Medicine ER -